Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6683
|
pubmed:dateCreated |
1998-6-15
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0028-0836
|
pubmed:issnType |
Print
|
pubmed:day |
28
|
pubmed:volume |
393
|
pubmed:owner |
NLM
|
pubmed:pagination |
291
|
pubmed:dateRevised |
2005-10-13
|
pubmed:meshHeading |
pubmed-meshheading:9620784-Antineoplastic Agents,
pubmed-meshheading:9620784-Biotechnology,
pubmed-meshheading:9620784-Drug Approval,
pubmed-meshheading:9620784-Great Britain,
pubmed-meshheading:9620784-Humans,
pubmed-meshheading:9620784-Investments,
pubmed-meshheading:9620784-Pancreatitis,
pubmed-meshheading:9620784-Phenylalanine,
pubmed-meshheading:9620784-Thiophenes
|
pubmed:year |
1998
|
pubmed:articleTitle |
Caveat investor.
|
pubmed:publicationType |
Editorial
|